Screener / SEC EDGAR /CIK 0001773751 /10-K filed Feb 23, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Offices & Clinics of Doctors of Medicine

Hims & Hers Health, Inc. HIMS

Launched in 2017, Hims & Hers Health, Inc. (and together with its subsidiaries, “Hims & Hers”, the “Company”, “we”, “us” or “our”) has built a consumer-first platform transforming the way customers fulfill their health and wellness needs. 10-K, Item 1

Headquarters
San Francisco, CA
CEO
Andrew Dudum
Next results
around Feb 22, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $2.3B through the costs to a net profit of $128.4M · income statement of the 10-K

4% operating margin
Revenue to Gross profit: $1.7BRevenue to Cost of revenue: $614.3MGross profit to Operating profit: $105.6MGross profit to Operating expenses: $1.6BOperating profit to Net profit: $105.6MOther income to Net profit: $22.8M Revenue: $2.3B REVENUE $2.3B +59% Y/Y Gross profit: $1.7B · 74% margin GROSS PROFIT $1.7B 74% margin · +48% Y/Y Cost of revenue: $614.3M · 26% of revenue COST OF REVENUE $614.3M 26% of revenue Operating profit: $105.6M · 4% margin OPERATING PROFIT $105.6M 4% margin · +71% Y/Y Other income: $22.8M · 1% of revenue OTHER INCOME $22.8M 1% of revenue Operating expenses: $1.6B · 69% of revenue OPERATING EXPENSES $1.6B 69% of revenue Net profit: $128.4M · 5% margin NET PROFIT $128.4M 5% margin · +2% Y/Y
Gross profit $1.7B 74% margin · +48% Y/Y
Operating profit $105.6M 4% margin · +71% Y/Y
Net profit $128.4M 5% margin · +2% Y/Y
The full income statement, year by year

HIMS among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 59.0%, above 92% of 154 peers (their median 10.4%) REVENUE GROWTH 59.0% · above 92% Gross margin: 63.8%, above 50% of 107 peers (their median 63.4%) GROSS MARGIN 63.8% · above 50% Operating margin: -8.1%, above 20% of 138 peers (their median 10.2%) OPERATING MARGIN -8.1% · above 20% Net margin: -6.7%, above 21% of 153 peers (their median 6.8%) NET MARGIN -6.7% · above 21% FCF margin: 0.3%, above 19% of 144 peers (their median 10.1%) FCF MARGIN 0.3% · above 19% Return on capital: 30.8%, above 96% of 89 peers (their median 9.0%) RETURN ON CAPITAL 30.8% · above 96%
HIMS Peer median Below the median

What changed

53 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 23, 2026 against Feb 24, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +426.2% ($6.1M to $32.1M) vs revenue +59.0% ($1.5B to $2.3B), +367.2 pts apart
  • Critical audit matters changed
    New this year: Assessment of the acquisition date fair value of the platform partnerships intangible asset acquired in a business combination (“As discussed in Note 3 to the consolidated financial statements, in July 2025, the Company acquired all of the outstanding equity of Zava for a purchase price of $258.0 million. The acquisition was accounted for as a business combination using the acquisition method of accounting with the purchase p”). No longer listed: Realizability of domestic deferred tax assets
  • Cash from operations $300.0M vs net income $128.4M (FY ending Dec 31, 2025)
8 more checks with nothing to note
  • Inventory +24.4% ($64.4M to $80.1M) vs revenue +59.0% ($1.5B to $2.3B), -34.6 pts apart
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

53 paragraphs in Risk Factors that were not in the 10-K filed Feb 24, 2025. Quoted as filed.

All 53 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
    The evolving regulatory landscape has also impacted our ability to continue offering access to such products. For example, in the United States, all doses of semaglutide branded under Ozempic and Wegovy became listed as available on the FDA’s shortage list as of October 30, 2024. On February 21, 2025, the FDA resolved the semaglutide…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
    Promoting prescription medicines via influencers is strictly prohibited in the United Kingdom, the European Union, and Canada. Regulators have increased scrutiny of social media posts, sponsored content, and discount codes that illegally advertise prescription medicines to the public, particularly for high-profile prescription medicines…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
    In the United Kingdom, pharmacies, pharmacists, and pharmacy technicians are regulated by the GPhC, which sets standards for the safe and effective provision of pharmacy services, including those provided at a distance (such as online and mail-order pharmacies). Pharmacies must be registered with the GPhC and are subject to regular…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
    The planned acquisition of Eucalyptus is subject to conditions, some or all of which may not be satisfied or completed on a timely basis, if at all. Completion of the planned acquisition of Eucalyptus (the “Proposed Acquisition”) is subject to the satisfaction or waiver of customary and other closing conditions, including regulatory…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$526.9M$872.0M$1.5B$2.3B
Net income−$65.7M−$23.5M$126.0M$128.4M
Operating cash flow−$26.5M$73.5M$251.1M$300.0M
Free cash flow−$33.7M$47.0M$198.3M$57.4M

Revenue, FY2019 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.3B ▲ 59.0% in FY2025

FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

6 filings in the last 30 days · SEC EDGAR

All filings
1 more

About the company

Hims & Hers Health, Inc., San Francisco, CA · from the 10-K filed Feb 23, 2026

Launched in 2017, Hims & Hers Health, Inc. (and together with its subsidiaries, “Hims & Hers”, the “Company”, “we”, “us” or “our”) has built a consumer-first platform transforming the way customers fulfill their health and wellness needs. We believe that the Company has the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format.

Headquarters
San Francisco, CA
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 9, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 24, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HIMS/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.